New Drug Provides Total Protection From H.I.V. in Trial of Young African Women
What is the new antiviral drug mentioned in the news?
The new antiviral drug mentioned in the news is lenacapavir, which is a twice-yearly injection that showed total protection from H.I.V. infection in young women in a large clinical trial in Africa. The trial, called Purpose 1, was conducted in Uganda and South Africa and compared lenacapavir's effectiveness to two other daily pills in wide use in high-income countries.
How often is the lenacapavir injection administered?
The lenacapavir injection is administered twice a year, providing protection from HIV infection for young women. This dosing regimen was tested in a large clinical trial called Purpose 1, conducted in Uganda and South Africa, and showed total protection from the virus.
Where was the Purpose 1 clinical trial conducted?
The Purpose 1 clinical trial was conducted in Uganda and South Africa. It aimed to test the efficacy of a twice-yearly injection of lenacapavir in providing better protection against HIV infection compared to two other widely used daily pill drugs.